These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 28474408)

  • 1. Efficacy of sofosbuvir and ledipasvir in an HCV+ gastro-resected patient.
    Taibi C; Tempestilli M; D'Avolio A; Garbuglia AR; De Nicolò A; Montalbano M; D'Offizi G
    J Clin Pharm Ther; 2017 Oct; 42(5):621-623. PubMed ID: 28474408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cure with ledipasvir/sofosbuvir for chronic hepatitis C virus in an individual with gastric bypass.
    Johnson SW; Teachey AL; Valanejad SM; Griffin SM; Weber SF
    J Clin Pharm Ther; 2017 Oct; 42(5):624-626. PubMed ID: 28474386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV.
    Tadokoro T; Morishita A; Fujita K; Oura K; Sakamoto T; Nomura T; Tani J; Yoneyama H; Masaki T
    Intern Med; 2018 Apr; 57(8):1101-1104. PubMed ID: 29279506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of ledipasvir/sofosbuvir in real-world patients with chronic hepatitis C: a collaborative treatment approach.
    Johnson SW; Ammirati SR; Hartis CE; Weber SF; Morgan MR; Darnell TA; Silwal A; Schmidlin HN; Priest DH
    Int J Antimicrob Agents; 2017 Jun; 49(6):778-781. PubMed ID: 28389353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perspectives of fixed daily dose of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C.
    Floreani A
    Expert Opin Pharmacother; 2015 Apr; 16(6):801-4. PubMed ID: 25728621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sofosbuvir/Ledipasvir Without Ribavirin Achieved High Sustained Virologic Response for Hepatitis C Recurrence After Liver Transplantation: Two-Center Experience.
    Elfeki MA; Abou Mrad R; Modaresi Esfeh J; Zein NN; Eghtesad B; Zervos X; Hanouneh IA; O'Shea R; Carey WD; Alkhouri N
    Transplantation; 2017 May; 101(5):996-1000. PubMed ID: 27631598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients.
    Kwok RM; Ahn J; Schiano TD; Te HS; Potosky DR; Tierney A; Satoskar R; Robertazzi S; Rodigas C; Lee Sang M; Wiegel J; Patel N; Gripshover J; Hassan MA; Branch A; Smith CI
    Liver Transpl; 2016 Nov; 22(11):1536-1543. PubMed ID: 27543748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens.
    Wyles D; Pockros P; Morelli G; Younes Z; Svarovskaia E; Yang JC; Pang PS; Zhu Y; McHutchison JG; Flamm S; Lawitz E
    Hepatology; 2015 Jun; 61(6):1793-7. PubMed ID: 25846014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.
    Fraser I; Burger J; Lubbe M; Dranitsaris G; Sonderup M; Stander T
    Pharmacoeconomics; 2016 Apr; 34(4):403-17. PubMed ID: 26666639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials.
    Alqahtani SA; Afdhal N; Zeuzem S; Gordon SC; Mangia A; Kwo P; Fried M; Yang JC; Ding X; Pang PS; McHutchison JG; Pound D; Reddy KR; Marcellin P; Kowdley KV; Sulkowski M
    Hepatology; 2015 Jul; 62(1):25-30. PubMed ID: 25963890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
    Manns M; Samuel D; Gane EJ; Mutimer D; McCaughan G; Buti M; Prieto M; Calleja JL; Peck-Radosavljevic M; Müllhaupt B; Agarwal K; Angus P; Yoshida EM; Colombo M; Rizzetto M; Dvory-Sobol H; Denning J; Arterburn S; Pang PS; Brainard D; McHutchison JG; Dufour JF; Van Vlierberghe H; van Hoek B; Forns X;
    Lancet Infect Dis; 2016 Jun; 16(6):685-697. PubMed ID: 26907736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
    Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
    Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
    Afdhal N; Zeuzem S; Kwo P; Chojkier M; Gitlin N; Puoti M; Romero-Gomez M; Zarski JP; Agarwal K; Buggisch P; Foster GR; Bräu N; Buti M; Jacobson IM; Subramanian GM; Ding X; Mo H; Yang JC; Pang PS; Symonds WT; McHutchison JG; Muir AJ; Mangia A; Marcellin P;
    N Engl J Med; 2014 May; 370(20):1889-98. PubMed ID: 24725239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
    Charlton M; Everson GT; Flamm SL; Kumar P; Landis C; Brown RS; Fried MW; Terrault NA; O'Leary JG; Vargas HE; Kuo A; Schiff E; Sulkowski MS; Gilroy R; Watt KD; Brown K; Kwo P; Pungpapong S; Korenblat KM; Muir AJ; Teperman L; Fontana RJ; Denning J; Arterburn S; Dvory-Sobol H; Brandt-Sarif T; Pang PS; McHutchison JG; Reddy KR; Afdhal N;
    Gastroenterology; 2015 Sep; 149(3):649-59. PubMed ID: 25985734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
    Kowdley KV; Gordon SC; Reddy KR; Rossaro L; Bernstein DE; Lawitz E; Shiffman ML; Schiff E; Ghalib R; Ryan M; Rustgi V; Chojkier M; Herring R; Di Bisceglie AM; Pockros PJ; Subramanian GM; An D; Svarovskaia E; Hyland RH; Pang PS; Symonds WT; McHutchison JG; Muir AJ; Pound D; Fried MW;
    N Engl J Med; 2014 May; 370(20):1879-88. PubMed ID: 24720702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials.
    Younossi ZM; Stepanova M; Marcellin P; Afdhal N; Kowdley KV; Zeuzem S; Hunt SL
    Hepatology; 2015 Jun; 61(6):1798-808. PubMed ID: 25627448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
    Globke B; Raschzok N; Teegen EM; Pratschke J; Schott E; Eurich D
    Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis.
    Reddy KR; Bourlière M; Sulkowski M; Omata M; Zeuzem S; Feld JJ; Lawitz E; Marcellin P; Welzel TM; Hyland R; Ding X; Yang J; Knox S; Pang P; Dvory-Sobol H; Subramanian GM; Symonds W; McHutchison JG; Mangia A; Gane E; Mizokami M; Pol S; Afdhal N
    Hepatology; 2015 Jul; 62(1):79-86. PubMed ID: 25846144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sofosbuvir/ledipasvir fixed-dose combination for treatment of chronic hepatitis C virus infection in children.
    Rizza SA; Nehra V; Temesgen Z
    Drugs Today (Barc); 2017 Aug; 53(8):447-451. PubMed ID: 29119149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C.
    Fazel Y; Lam B; Golabi P; Younossi Z
    Expert Opin Drug Saf; 2015 Aug; 14(8):1317-26. PubMed ID: 26043900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.